Runge, Kimon http://orcid.org/0000-0002-0263-4360
Reisert, Marco
Feige, Bernd http://orcid.org/0000-0002-9436-1258
Nickel, Kathrin http://orcid.org/0000-0001-9863-317X
Urbach, Horst
Venhoff, Nils http://orcid.org/0000-0001-7729-2759
Tzschach, Andreas http://orcid.org/0000-0002-6840-965X
Schiele, Miriam A.
Hannibal, Luciana http://orcid.org/0000-0002-0911-5758
Prüss, Harald http://orcid.org/0000-0002-8283-7976
Domschke, Katharina http://orcid.org/0000-0002-2550-9132
Tebartz van Elst, Ludger http://orcid.org/0000-0002-2274-5447
Endres, Dominique http://orcid.org/0000-0001-7322-1195
Funding for this research was provided by:
Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
Article History
Received: 5 November 2022
Revised: 7 February 2023
Accepted: 13 February 2023
First Online: 7 March 2023
Competing interests
: HU: Speaker fees from Bayer AG, Bracco, Eisai, Stryker, and UCB Pharma. KD: Steering Committee Neurosciences, Janssen. Speaker fees from Janssen. LTvE: Advisory boards, lectures, or travel grants within the last three years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen and Cyberonics. All other authors have no potential conflicts of interest to declare.